A
Company · Healthtech & Bio
AzureBio
AzureBio (AzureBio S.L.) was a Madrid-based (Tres Cantos) biotech company founded in 2007 that provided drug and vaccine formulation/stabilisation services to the pharma and biotech industries and developed medical devices, including a biodegradable solid-needle system for percutaneous vaccine and drug administration. The company raised roughly $1.67M from institutional investors but entered voluntary bankruptcy proceedings in 2017 and is now formally dissolved ("extinguida").
Founded
2007
Founders
1
News
0
Rounds
0
Investors
3
SectorsHealthtech & Bio, Medical Devices, Drug Delivery, Biotechnology
Start-up MapHealthtech & Bio › R&D tools & software for life sciences
Profile updated 30 Jul 2026
Founders
A
Arcadio García de Castro Andrews
Founder & CEO
Global models 5
C
Corium International
United States · www.coriumintl.com ↗
Venture-backed transdermal/microneedle drug delivery and formulation company, the closest analogue to AzureBio's stabilisation-and-delivery technology model before being acquired for ~$504M.
$235MComparable
VVaxxas
Australia · www.vaxxas.com ↗
Develops needle-free, high-density microarray patch technology for vaccine delivery, matching AzureBio's needle-free/solid-needle drug and vaccine administration platform.
$154MComparable
ZZosano Pharma
United States · www.zosanopharma.com ↗
Built a proprietary transdermal microneedle patch system for systemic drug delivery, directly comparable to AzureBio's medical-device delivery technology.
$147MComparable
VVaxess Technologies
United States · www.vaxess.com ↗
Develops thermostable, needle-free vaccine and drug patches, matching AzureBio's core focus on drug/vaccine stabilisation and needle-free delivery.
$100MComparable
MMicron Biomedical
United States · micronbiomedical.com ↗
Spin-out microneedle patch company for vaccine and drug delivery, a smaller-scale comparable to AzureBio's stabilisation and delivery-device business.
$16MComparable
Investors 3
Funding rounds
No announced rounds on record.
News & media
No coverage on record yet.


